Phase 3Completed
Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration (ARI2)
A Phase III b, Multicenter Study of the Efficacy and Safety of Aflibercept Switch in Patients With Exudative AMD With Detachment of the Retinal Pigment Epithelium and Previously Treated With Ranibizumab Intravitreal Injection. (ARI2)
- Sponsor
- Centre Hospitalier Intercommunal Creteil (Academic or other)
- Enrolment
- 84 enrolled
- Conditions
- Macular Degeneration; Wet Macular Degeneration; Retinal Degeneration; Retinal Diseases; Eye Diseases
- Interventions
- Aflibercept
- Ages
- adults, older adults
- Registry
- NCT02157077
From the registry
The purpose of the current study is to evaluate the ability of Eylea to induce a regression of PED height on patients previously extensively treated by Lucentis. The regimen proposed for this study is the 3 monthly injection followed by a 6 weeks interval injection until week 26.
Primary outcomes
- Change From Baseline in Maximal Height of Pigment Epithelium Detachment (PED) at 12 Weeks